Sort   by:  
 Page size 
ProteomicsTranslatome proteomics of human AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25% of acute myeloid leukemia (AML) patients and lead to constitutive activation of FLT3, driving leukemia cell survival and proliferation. Quizartinib, crenolanib and gilteritinib are second-generation FLT3 inhibitors ...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD023125 | Pride
Human Lc-msms Flt3 Aml 
ProteomicsPhosphoproteomics of human MV4-11 AML cells treated with Gilteritinib
Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25% of acute myeloid leukemia (AML) patients and lead to constitutive activation of FLT3, driving leukemia cell survival and proliferation. Quizartinib, crenolanib and gilteritinib are second-generation FLT3 inhibitors ...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD023123 | Pride
Human Lc-msms Flt3 Aml 
ProteomicsPhosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) were obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were treated with FLT3 inhibitor gilteritinib (or DMSO vehicle control) at 10 nM concentration for 6 h, followed b...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034080 | Pride
Aml Gilteritinib Flt3 
ProteomicsTranslatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. Cells were treated ex vivo with DMSO vehicle control or 10 nM FLT3 inhibitors quizartinib, crenolanib, gilteritinib for 6 hour...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034081 | Pride
Aml Gilteritinib Flt3 Translatome Quizartinib Crenolanib 
ProteomicsMYC as a Key Regulator of Protein Synthesis: Characterization of Downstream Targets in Multiple Myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder and frequently characterized by the 16 dysregulation of the MYC oncogene, which is associated with poor prognosis and disease progression. While MYC's involvement in transcriptional regulation is well-established, the functional role of MYC t...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-06-15 | MSV000092169 | MassIVE
Sort   by:  
 Page size